Clinical Trial Update: Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

View source ↗

Summary

A regulatory post-marketing surveillance study (rPMS) is planned to evaluate the safety and effectiveness of semaglutide (Ozempic) in type 2 diabetes patients i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Status: NOT_YET_RECRUITING